IDEXX Laboratories, Inc. $IDXX Stock Bought by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management increased its IDEXX Laboratories stake by 39.9% in the third quarter, adding 73,129 shares to own 256,362 shares valued at approximately $133.9 million. Institutional investors collectively hold 87.84% of the company.
• Analysts maintain a generally positive view, with seven Buy ratings and five Holds, producing a consensus “Moderate Buy” rating and an average price target of $744.09. Recent targets included JPMorgan’s reduction to $750 and Citigroup’s increase to $670.
• IDEXX reported stronger-than-expected quarterly results, with EPS of $4.27 versus the $3.94 consensus and revenue of $1.22 billion, up 9.7% year over year. Shares opened at $560.36, while the company’s FY 2026 EPS guidance is $14.69–$14.94.

Assenagon Asset Management S.A. raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 39.9% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 256,362 shares of the company's stock after buying an additional 73,129 shares during the quarter. Assenagon Asset Management S.A. owned about 0.33% of IDEXX Laboratories worth $133,870,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of IDXX. Fort Washington Investment Advisors Inc. OH purchased a new position in shares of IDEXX Laboratories in the 3rd quarter valued at about $538,000. Birchbrook Inc. increased its position in shares of IDEXX Laboratories by 0.6% in the third quarter. Birchbrook Inc. now owns 4,505 shares of the company's stock valued at $2,352,000 after buying an additional 28 shares in the last quarter. Signal Advisors Wealth LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth $265,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth $207,000. Finally, NorthCrest Asset Manangement LLC boosted its position in shares of IDEXX Laboratories by 57.9% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 627 shares of the company's stock worth $322,000 after buying an additional 230 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Citigroup increased their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, October 8th. Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. KeyCorp initiated coverage on IDEXX Laboratories in a research note on Monday. They issued a "sector weight" rating on the stock. Finally, JPMorgan Chase & Co. lowered their target price on IDEXX Laboratories from $775.00 to $750.00 and set an "overweight" rating on the stock in a report on Friday. Seven equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $744.09.

Insider Activity at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares of the company's stock, valued at $5,090,941.44. The trade was a 18.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.79% of the stock is currently owned by company insiders.

IDEXX Laboratories Trading Up 2.4%

Shares of IDXX opened at $560.36 on Friday. The stock has a fifty day moving average of $534.22 and a two-hundred day moving average of $551.84. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The company has a market capitalization of $44.15 billion, a PE ratio of 38.48, a price-to-earnings-growth ratio of 2.92 and a beta of 1.55. IDEXX Laboratories, Inc. has a fifty-two week low of $500.61 and a fifty-two week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The business had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.20 billion. During the same quarter last year, the firm earned $3.50 earnings per share. The business's revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 14.80 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX's companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.